Rick Rink
Research Subjects
Research Interests
Rick Rink has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Annechien Plat
BioMade Technology Foundation, Nijenborgh 4, 9747 AG Groningen, The Netherlands
1 shared publication - Anneke Kuipers
BioMade Technology Foundation, Nijenborgh 4, 9747 AG Groningen, The Netherlands
1 shared publication - Gert N. Moll
LanthioPep, Nijenborgh 4, 9747 AG Groningen, the Netherlands
1 shared publication - Jacobien G. de Lange
BioMade Technology Foundation, Nijenborgh 4, 9747 AG Groningen, The Netherlands
1 shared publication
Latest Publications
- Open Access
Activity and Export of Engineered Nisin-(1-22) Analogs
The pentacyclic peptide antibiotic nisin, produced by Lactococcus lactis is ubiquitously applied as a food preservative. We previously demonstrated that the truncated nisin-(1-22) has only 10-fold lower activity than nisin. Here we aimed at further developing this tricyclic nisin analog to reach activity comparable to that of nisin. Our data demonstrate that: (1) ring A has a large mutational freedom; (2) the composition of residues 20–22 strongly affects production levels of nisin-(1-22); (3) a positively charged C-terminus of nisin-(1-22) significantly enhances its antimicrobial activity; (4) nisin-(1-22) inhibits in vitro growth of a target strain using different dynamics than nisin.
Open AccessActivity and Export of Engineered Nisin-(1-22) Analogs
The pentacyclic peptide antibiotic nisin, produced by Lactococcus lactis is ubiquitously applied as a food preservative. We previously demonstrated that the truncated nisin-(1-22) has only 10-fold lower activity than nisin. Here we aimed at further developing this tricyclic nisin analog to reach activity comparable to that of nisin. Our data demonstrate that: (1) ring A has a large mutational freedom; (2) the composition of residues 20–22 strongly affects production levels of nisin-(1-22); (3) a positively charged C-terminus of nisin-(1-22) significantly enhances its antimicrobial activity; (4) nisin-(1-22) inhibits in vitro growth of a target strain using different dynamics than nisin.